NO20053215L - Pyrazolderivater med anvendelse som COX-1-inhibitorer. - Google Patents

Pyrazolderivater med anvendelse som COX-1-inhibitorer.

Info

Publication number
NO20053215L
NO20053215L NO20053215A NO20053215A NO20053215L NO 20053215 L NO20053215 L NO 20053215L NO 20053215 A NO20053215 A NO 20053215A NO 20053215 A NO20053215 A NO 20053215A NO 20053215 L NO20053215 L NO 20053215L
Authority
NO
Norway
Prior art keywords
cox
inhibitors
pyrazole derivatives
lower alkyl
hydroxy
Prior art date
Application number
NO20053215A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053215D0 (no
Inventor
Fumiyuki Shirai
Hidenori Azami
Natsuko Kayakiri
Kazuo Okumura
Katsuya Nakamura
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002953019A external-priority patent/AU2002953019A0/en
Priority claimed from AU2002953602A external-priority patent/AU2002953602A0/en
Priority claimed from AU2003902015A external-priority patent/AU2003902015A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20053215D0 publication Critical patent/NO20053215D0/no
Publication of NO20053215L publication Critical patent/NO20053215L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20053215A 2002-12-02 2005-06-30 Pyrazolderivater med anvendelse som COX-1-inhibitorer. NO20053215L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2002953019A AU2002953019A0 (en) 2002-12-02 2002-12-02 Azole derivatives
AU2002953602A AU2002953602A0 (en) 2002-12-30 2002-12-30 New compounds
AU2003902015A AU2003902015A0 (en) 2003-04-29 2003-04-29 Azole derivatives
PCT/JP2003/014489 WO2004050632A1 (en) 2002-12-02 2003-11-14 Pyrazole derivatives useful as cox-i inhibitors

Publications (2)

Publication Number Publication Date
NO20053215D0 NO20053215D0 (no) 2005-06-30
NO20053215L true NO20053215L (no) 2005-09-01

Family

ID=32474716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053215A NO20053215L (no) 2002-12-02 2005-06-30 Pyrazolderivater med anvendelse som COX-1-inhibitorer.

Country Status (15)

Country Link
US (2) US7183306B2 (pl)
EP (1) EP1567503B1 (pl)
JP (1) JP4419078B2 (pl)
KR (1) KR20050083761A (pl)
AR (1) AR042273A1 (pl)
AT (1) ATE538097T1 (pl)
BR (1) BR0316332A (pl)
CA (1) CA2505945A1 (pl)
ES (1) ES2379076T3 (pl)
MX (1) MXPA05005742A (pl)
NO (1) NO20053215L (pl)
NZ (1) NZ540515A (pl)
PL (1) PL377778A1 (pl)
TW (1) TW200410942A (pl)
WO (1) WO2004050632A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517870A (ja) * 2001-01-02 2004-06-17 藤沢薬品工業株式会社 シクロオキシゲナーゼ阻害剤
ATE538097T1 (de) 2002-12-02 2012-01-15 Astellas Pharma Inc Als cox-i-inhibitoren geeignete pyrazolderivate
DE602004028800D1 (en) 2003-02-07 2010-10-07 Daiichi Sankyo Co Ltd Pyrazolderivat
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
EP1718617B1 (en) * 2004-02-20 2009-08-19 AstraZeneca AB 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
MX2007000016A (es) * 2004-07-01 2007-03-27 Daiichi Seiyaku Co Derivados de pirazol.
WO2006013962A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 抗血小板薬およびその製造方法
EP1845972A4 (en) * 2005-01-10 2010-12-22 Univ Connecticut CANNAPINOID RECEPTORS APPLYING NOVEL HETEROPYRROL ANALOGS
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0516661D0 (en) * 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
EP2009006A4 (en) 2006-03-27 2010-01-27 Toray Industries UREIDE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
US20100069443A1 (en) * 2006-09-07 2010-03-18 National University Corporation Okayama University Compound with benzamide skeleton having cyclooxygenase-1 (cox-1)-selective inhibitory activity
WO2008075019A1 (en) * 2006-12-18 2008-06-26 7Tm Pharma A/S Modulators of cb1 receptors
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008105383A1 (ja) * 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
JPWO2008114859A1 (ja) * 2007-03-22 2010-07-08 アステラス製薬株式会社 ピラゾール誘導体を含有する医薬組成物
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
WO2009099670A2 (en) * 2008-02-08 2009-08-13 Nektar Therapeutics Al, Corporation Oligomer-cannabinoid conjugates
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
CN102076650A (zh) 2008-06-25 2011-05-25 第一三共株式会社 羧酸化合物
US20120046356A1 (en) * 2008-10-02 2012-02-23 Cambrex Karlskoga Ab New process for preparing diketones and medicaments
TWI435874B (zh) 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
JP6994498B2 (ja) 2016-08-15 2022-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ３－アミノ－１－（２，６－二置換フェニル）ピラゾール類を調製する方法
US11339142B2 (en) 2016-09-07 2022-05-24 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN115611790A (zh) * 2022-10-31 2023-01-17 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种甲硫基甲基苯基醚的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5164381A (en) * 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5051518A (en) * 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5298521A (en) * 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
JPH10509140A (ja) 1994-11-08 1998-09-08 エーザイ株式会社 ピラゾール誘導体
ES2136018B1 (es) 1997-06-17 2000-07-01 Menarini Lab Compuestos inhibidores selectivos de la ciclooxigenasa-i y su utilizacion como analgesicos, antiinflamatorios y antiartriticos.
WO1999062885A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
WO2000018741A2 (en) * 1998-09-30 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds as cox-2 inhibitors
WO2000066562A1 (en) 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
PT1104759E (pt) * 1999-12-03 2004-01-30 Pfizer Prod Inc Compostos heteroaril-fenil-pirazole como agentes anti-inflamatorios e analgesicos
EP1276736A2 (en) * 2000-04-25 2003-01-22 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
JP2004517870A (ja) 2001-01-02 2004-06-17 藤沢薬品工業株式会社 シクロオキシゲナーゼ阻害剤
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
MXPA04009463A (es) * 2002-04-05 2005-01-25 Cadila Healthcare Ltd Nuevos compuestos heterociclicos, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina.
ATE538097T1 (de) 2002-12-02 2012-01-15 Astellas Pharma Inc Als cox-i-inhibitoren geeignete pyrazolderivate
CN100421632C (zh) 2005-02-01 2008-10-01 金磊 人工心脏瓣膜成形环

Also Published As

Publication number Publication date
ATE538097T1 (de) 2012-01-15
NZ540515A (en) 2008-01-31
JP2006514095A (ja) 2006-04-27
BR0316332A (pt) 2005-09-27
KR20050083761A (ko) 2005-08-26
US20070112037A1 (en) 2007-05-17
MXPA05005742A (es) 2005-08-16
CA2505945A1 (en) 2004-06-17
US20040116475A1 (en) 2004-06-17
HK1087102A1 (zh) 2006-10-06
NO20053215D0 (no) 2005-06-30
PL377778A1 (pl) 2006-02-20
WO2004050632A1 (en) 2004-06-17
EP1567503B1 (en) 2011-12-21
EP1567503A1 (en) 2005-08-31
ES2379076T3 (es) 2012-04-20
US7183306B2 (en) 2007-02-27
JP4419078B2 (ja) 2010-02-24
TW200410942A (en) 2004-07-01
AR042273A1 (es) 2005-06-15

Similar Documents

Publication Publication Date Title
NO20053215L (no) Pyrazolderivater med anvendelse som COX-1-inhibitorer.
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
WO2008007122A3 (en) Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
NO20062031L (no) Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media
NO20074296L (no) 4-cyklopropyl-1,2,3-tiadiazolforbindelse, agrohortikulturelt plantesykdoms-kontrollmiddel og fremgangsmate for anvendelse av det samme
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
NO20064326L (no) Aryl- og heteroarylpiperidinkarboksylatderivater, deres fremstilling og anvendelse derav i form av FAAH enzyminhibitorer
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
WO2004046122A3 (en) Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
WO2002028844A1 (en) Thiazole or oxazole derivatives
TW200505446A (en) Inhibitor of cox
EP1671957A4 (en) THIADIAZOLINDERIVATE
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
SE8305160L (sv) Antibakteriella emnen
ATE446295T1 (de) 2-amino-4-pyridylmethyl-thiazolinderivate und ihre verwendung als induzierbare no-synthase inhibitoren
ATE445619T1 (de) Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren
WO2004099130A3 (en) 1,2-diarylimidazoles useful as inhibitors of cox
PL1904469T3 (pl) Nowe pochodne pirokatechiny
EP1613610B8 (en) Benzo 1,2,5 oxadiazoles and benzo 1,2,5 thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

FC2A Withdrawal, rejection or dismissal of laid open patent application